Summit Therapeutics(MX:SMMT)
MX$290.000.00 (0.00%)
MX:SMMT
Summit Therapeutics financials statements
MX$290.00
At close:0.00 (0.00%)
Summit Therapeutics (SMMT) Ratios
1 Followers
Summit Therapeutics Ratios
MX:SMMT's free cash flow for Q3 2026 was £-160.21M. For the 2026 fiscal year, MX:SMMT's free cash flow was decreased by £-396.00K and operating cash flow was £-159.81M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 9.87 | 10.15 | 9.30 | 16.93 | 3.80 |
| Quick Ratio | 9.87 | 10.15 | 9.30 | 16.93 | 3.52 |
| Cash Ratio | 3.09 | 2.51 | 3.50 | 8.99 | 2.80 |
| Solvency Ratio | -11.69 | -4.72 | -4.91 | -0.14 | -2.86 |
| Operating Cash Flow Ratio | -4.42 | -3.41 | -3.76 | -1.07 | -2.83 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -2.10 | -255.37 |
| Net Current Asset Value | £ 627.98M | £ 301.21M | £ 64.45M | £ 119.20M | £ 67.22M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.02 | 0.52 | 0.78 | 0.02 |
| Debt-to-Equity Ratio | 0.03 | 0.02 | 1.37 | 4.10 | 0.03 |
| Debt-to-Capital Ratio | 0.03 | 0.02 | 0.58 | 0.80 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.56 | 0.80 | 0.00 |
| Financial Leverage Ratio | 1.14 | 1.12 | 2.61 | 5.24 | 1.36 |
| Debt Service Coverage Ratio | 0.00 | -19.39 | -4.16 | -3.03 | -151.98 |
| Interest Coverage Ratio | 0.00 | -20.78 | -5.45 | -13.55 | -306.71 |
| Debt to Market Cap | 0.00 | 0.00 | 0.06 | 0.63 | 0.00 |
| Interest Debt Per Share | 0.03 | 0.02 | 0.20 | 2.71 | 0.03 |
| Net Debt to EBITDA | 0.19 | 0.46 | -0.50 | -2.33 | 0.80 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | -256.99% | 100.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | -10561.06% | -4884.47% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | -10381.73% | -4748.76% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | -8467.05% | -4764.29% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | -11185.94% | -4897.84% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | -11185.94% | -4897.84% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | -11185.94% | -4897.84% |
| Net Income Per EBT | 100.00% | 100.00% | 99.85% | 100.00% | 100.00% |
| EBT Per EBIT | 98.64% | 97.93% | 686.32% | 132.11% | 102.80% |
| Return on Assets (ROA) | -143.72% | -50.79% | -303.00% | -11.86% | -78.15% |
| Return on Equity (ROE) | -163.86% | -56.91% | -791.49% | -62.20% | -106.39% |
| Return on Capital Employed (ROCE) | -161.37% | -57.36% | -49.16% | -9.54% | -98.22% |
| Return on Invested Capital (ROIC) | -160.56% | -56.82% | -48.34% | -9.22% | -97.01% |
| Return on Tangible Assets | -144.10% | -51.01% | -305.85% | -11.89% | -87.75% |
| Earnings Yield | -8.26% | -1.39% | -38.02% | -9.59% | -35.71% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.12 | 0.07 |
| Payables Turnover | 0.00 | 0.00 | 0.77 | 7.08 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.14 | 0.52 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Cash Conversion Cycle | 0.00 | 0.00 | -474.86 | 3117.55 | 4907.02 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 3169.09 | 4907.02 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 474.86 | 51.54 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 3169.09 | 4907.02 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.43 | -0.16 | -0.12 | -0.22 | -0.79 |
| Free Cash Flow Per Share | -0.43 | -0.16 | -0.12 | -0.22 | -0.79 |
| Dividend Paid and CapEx Coverage Ratio | -491.52 | -1022.35 | -599.69 | -66.64 | -237.21 |
| Capital Expenditure Coverage Ratio | -491.52 | -1022.35 | -599.69 | -66.64 | -237.21 |
| Operating Cash Flow Coverage Ratio | -15.46 | -19.69 | -0.72 | -0.08 | -26.09 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | -59.04 | -40.13 |
| Free Cash Flow Yield | -2.47% | -0.89% | -4.75% | -5.14% | -29.38% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -12.15 | -71.40 | -2.63 | -10.43 | -2.80 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 1166.67 | 137.16 |
| Price-to-Book (P/B) Ratio | 19.85 | 41.02 | 20.82 | 6.49 | 2.98 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -40.41 | -112.11 | -21.03 | -19.47 | -3.40 |
| Price-to-Operating Cash Flow Ratio | -40.50 | -112.22 | -21.07 | -19.76 | -3.42 |
| Price-to-Earnings Growth (PEG) Ratio | -0.03 | 1.05 | -0.02 | 0.18 | -0.11 |
| Enterprise Value Multiple | -11.93 | -75.19 | -23.79 | -13.56 | -2.09 |
| Enterprise Value | 12.87B | 12.67B | 1.65B | 991.83M | 179.11M |
| EV to EBITDA | -11.93 | -75.19 | -23.79 | -13.56 | -2.09 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 1408.27 | 99.01 |
| EV to Free Cash Flow | -39.78 | -111.43 | -21.49 | -23.50 | -2.46 |
| EV to Operating Cash Flow | -39.86 | -111.53 | -21.52 | -23.85 | -2.47 |
| Tangible Book Value Per Share | 0.88 | 0.43 | 0.12 | 0.65 | 0.77 |
| Shareholders’ Equity Per Share | 0.88 | 0.44 | 0.13 | 0.66 | 0.90 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Net Income Per Share | -1.44 | -0.25 | -0.99 | -0.41 | -0.96 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.05 | 8.85 | 1.06 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 73.83 | 47.18 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 37.91 | 13.05 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 14.03 | 5.23 |
| Income Quality | 0.30 | 0.64 | 0.12 | 0.53 | 0.82 |
Currency in GBP
